Journal of Pharmaceutical Policy and Practice最新文献

{"title":"Exploring consumer experiences of pharmacist prescribing - a scoping review.","authors":"Sheilpa Shivangani Sen, Bandana Saini, Betty Chaar","doi":"10.1080/20523211.2026.2733984","DOIUrl":"10.1080/20523211.2026.2733984","url":null,"abstract":"<p><strong>Introduction: </strong>The evolving scope of practice for pharmacists now encompasses a transition from traditional dispensing roles towards an integration of expanded clinical services, which include but are not limited to vaccinations, medication reviews, and prescribing. This scoping review aimed to explore the existing literature concerning consumer perceptions of pharmacist independent prescribing (PIP) from the patients who have experienced this service firsthand.</p><p><strong>Methods: </strong>The research question was developed, and relevant search terms, databases, and inclusion/exclusion criteria were systematically identified. This review followed the PRISMA guidelines (Tricco et al., 2018) and sources were searched from 2006 to 2026. Following the screening and full-text review processes, data was presented in a table form. The insights identified from consumers were grouped into themes. All screening was independently carried out by two members of the review team.</p><p><strong>Results: </strong>A systematic screening of the literature yielded 802 records, from which 19 papers met the inclusion criteria for full-text review, focusing specifically on consumer perspectives regarding their direct experience with PIP. The synthesis of these papers consistently indicated a favourable disposition among consumers concerning both the expanded PIP role and their utilisation experiences, tempered only by a few identified concerns.</p><p><strong>Conclusions: </strong>Given that Australia is still in the initial stages of implementing PIP, there is a need to give a voice to consumers. Overall, this review highlighted that consumers were largely supportive of the PIP role, and their experiences are mostly positive with this service. There is capacity to design and implement locally relevant studies to gauge the consumer perspectives of the PIP service and to identify ways to address the challenges and facilitate integration of PIPs in primary care.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2733984"},"PeriodicalIF":2.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13618192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149075129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory evolution and service delivery models of telepharmacy in Thailand: a review of pandemic responses and future policy directions.","authors":"Patama Tapchaisri, Anuchai Theeraroungchaisri","doi":"10.1080/20523211.2026.2731648","DOIUrl":"10.1080/20523211.2026.2731648","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic accelerated digital health adoption in Thailand, disrupting traditional healthcare delivery and prompting rapid pharmaceutical system reforms. Prior to 2020, telepharmacy was virtually non-existent due to strict regulations mandating in-person dispensing at licensed premises; however, the public health crisis prompted policy changes, leading to regulatory relaxation and the formal establishment of telepharmacy standards. To understand these transformative shifts, this review examines the regulatory evolution of telepharmacy in Thailand, classifies diverse service delivery models implemented across hospital and community pharmacy settings, and synthesises effectiveness evidence to inform future pharmaceutical policy and sustainable system integration.</p><p><strong>Methods: </strong>An integrative narrative review using documentary analysis of official policy and regulatory documents was conducted. Studies evaluating telepharmacy or medication delivery services were identified through PRISMA-guided searches of Thai-Journal Citation Index (TCI), PubMed, and Google Scholar (2020-2025).</p><p><strong>Results: </strong>Thailand implemented a phased policy response progressing from emergency regulatory flexibility toward institutionalised governance. Seven hospital-based telepharmacy models were identified. Synthesis of 31 included studies (14 pharmacist-led and 17 telemedicine with medication delivery or medication delivery without pharmacist counselling studies) suggested that telepharmacy and medication delivery services generally supported continuity of care for chronic diseases. Studies involving pharmacist interventions more frequently reported favourable outcomes, although findings varied across service models. Implementation relied largely on social media platforms and proprietary applications, though independent pharmacies faced financial barriers to accessing certified platforms.</p><p><strong>Conclusion: </strong>While telepharmacy has been integrated into routine care under the Universal Coverage Scheme (UCS), an institutionalisation gap remains regarding sustainable public financing and digital infrastructure. Addressing regulatory clarity, reimbursement mechanisms, digital equity, and platform interoperability will be essential for the long-term and equitable integration of telepharmacy.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2731648"},"PeriodicalIF":2.6,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13600311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated AHP-Delphi and Mini-HTA for selection of metabolic drugs in China's national medical insurance catalog: a framework towards quantitative dynamic adjustment.","authors":"Jiajin Li, Tianxiao Huang, Yujie Sun, Lu Yu","doi":"10.1080/20523211.2026.2701914","DOIUrl":"10.1080/20523211.2026.2701914","url":null,"abstract":"<p><strong>Background: </strong>China's high burden of metabolic disease requires more systematic approaches to selecting medicines for inclusion in the National Medical Insurance Catalog. Existing processes face difficulties in quantitatively balancing clinical value, target population needs, pharmacoeconomic evidence, and resource constraints, and may therefore rely heavily on subjective judgment.</p><p><strong>Methods: </strong>We developed a decision framework integrating the analytic hierarchy process (AHP), the Delphi method, and mini-health technology assessment (mini-HTA) principles. Candidate criteria were identified from the WHO Essential Medicines List, India's National List of Essential Medicines, the Kenya Essential Medicines List, China's National Medical Insurance Catalog, and relevant policy-oriented literature on drug selection in China. These criteria were used to construct a systematic and locally adapted framework. Three rounds of consultation were conducted with a multidisciplinary expert panel comprising one clinician, three pharmacists, and three health insurance administrators. Indicator weights were calculated using the geometric mean method. Expert agreement and judgment consistency were assessed using Kendall's coefficient of concordance (W) and consistency ratios (CR), respectively.</p><p><strong>Results: </strong>The framework included 14 primary indicators and 42 secondary indicators. Expert consensus was statistically significant (Kendall's W = 0.57, p < 0.001), and all consistency ratios were below 0.1, indicating acceptable consistency and robustness in weight allocation.</p><p><strong>Conclusions: </strong>The proposed AHP-Delphi-mini-HTA framework provides a quantitative and transparent approach to selecting metabolic drugs for insurance coverage in China. Although prospective pilot testing is still required, the framework supports standardized assessment, reduces reliance on subjective judgment, and may facilitate future integration of real-world evidence and AI-assisted decision-making.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2701914"},"PeriodicalIF":2.6,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13600306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A model for the clinical management of the introduction of new medicines in a large University Hospital in Spain.","authors":"Immaculada Danés, Antònia Agustí, Elena Ballarín, Patricia Marrero, Guillem Vancells, Salvador Clemente, Mar Vila, Sonia Cortés, María José Abadías, Maria Queralt Gorgas, Eduard Diogène","doi":"10.1080/20523211.2026.2730801","DOIUrl":"10.1080/20523211.2026.2730801","url":null,"abstract":"<p><strong>Background: </strong>New medicines offer therapeutic opportunities but also challenge healthcare system organisation and sustainability. This study aims to describe a model based on regular multidisciplinary meetings to manage and monitor the introduction of new medicines for Hospital Outpatient Treatments (HOT) in a Spanish tertiary hospital, and the observed results after its implementation.</p><p><strong>Methods: </strong>Meetings held during 2016-2023 and related documents were retrospectively reviewed. The meeting agenda and minutes included information on new drugs, follow-up of compliance with data collection in the Register of Patients and Treatments, drug expenditure, number of treated patients, quality/efficiency indicators, and agreements. An observational, descriptive study with a mixed approach (quantitative analysis of expenditure and activity data and qualitative documentary analysis) was performed. Percentage changes are expressed as relative changes.</p><p><strong>Results: </strong>During this period, 242 meetings with 12 selected clinical departments/units were held. A total of 284 agreements were reached, most of them related to the need to improve registry data (37.7%), and promoting the use of generic/biosimilar drugs (18.3%). A 40.2% increase in HOT expenditure, a 55.4% increase in the number of treated patients, and a 9.7% decrease in the cost per patient were documented in these departments from 2016 to 2023. The greatest HOT expenditure was observed in Haematology and Oncology (reaching around 39 and 28 million euros annually in 2023, respectively). The most marked increases occurred in Pneumology and Allergology. The use of generic/biosimilar drugs in Infectious diseases and Rheumatology departments had a more noticeable impact, with decreases in HOT expenditure of 15.8% and 6.6%, respectively. While caution is needed when interpreting the data, a lower increase in HOT expenditure was observed in the departments/units in which meetings were held.</p><p><strong>Conclusion: </strong>Having a consolidated method for the introduction and monitoring of new medications helps to set up an organised and reasoned decision-making process.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2730801"},"PeriodicalIF":2.6,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic and antiviral prescribing patterns among hospitalised patients with COVID-19 pneumonia in Mongolia: a real-world descriptive retrospective study.","authors":"Narangarav Nyamdag, Nina Muratkhan, Munkhbat Sukhee, Erdenetuya Myagmarsuren","doi":"10.1080/20523211.2026.2731647","DOIUrl":"10.1080/20523211.2026.2731647","url":null,"abstract":"<p><strong>Background: </strong>During the COVID-19 pandemic, Mongolia, like many low- and middle-income countries, faced major healthcare delivery challenges due to limited system readiness, resource constraints, geopolitical vulnerabilities, and prolonged border closures. These factors caused shortages of laboratory reagents and globally recommended therapeutics, including remdesivir and tocilizumab, prompting clinicians to use alternative antivirals and empirical broad-spectrum antibiotics.</p><p><strong>Objective: </strong>To evaluate and compare real-world prescribing patterns of antibiotics and antivirals among hospitalised patients with COVID-19 pneumonia at Mongolia's two largest tertiary referral facilities: Mongolia-Japan Hospital (MJH) and the National Center for Communicable Diseases (NCCD).</p><p><strong>Methods: </strong>This retrospective cross-sectional study analysed anonymised medical charts and electronic health records of 1012 adults with PCR-confirmed COVID-19 pneumonia hospitalised between 18 April and 31 December 2021. Demographics, comorbidities, laboratory markers, and pharmacological treatments were systematically extracted and compared between the two institutions.</p><p><strong>Results: </strong>Antibiotics were prescribed to 87.6% (887/1012) of patients. Cephalosporins were the most frequently prescribed class (89.3%, 904/1012), followed by macrolides (36.5%, 369/1012) and fluoroquinolones (33.5%, 339/1012). Multi-drug empiricism was common, with beta-lactam, macrolide, and quinolone combinations accounting for 70.8% (68/96) of triple-antibiotic regimens. Antivirals were administered to over 90% of patients, predominantly umifenovir (52.2%) and favipiravir, supported by domestic stockpiles and Eurasian trade networks. Remdesivir was rarely used, while tocilizumab was administered to only 2 patients (0.2%). Hypertension and diabetes were significantly more frequent in the MJH cohort, reflecting differences in catchment populations and screening practices.</p><p><strong>Conclusion: </strong>The high rate of empirical broad-spectrum antibiotic use and reliance on alternative antivirals reflect pragmatic clinical adaptations to diagnostic reagent shortages and therapeutic supply inequities. These findings highlight the need for national antimicrobial stewardship programmes, strengthened microbiological diagnostic capacity, and digitised clinical registries to improve healthcare system resilience in resource-constrained settings.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2731647"},"PeriodicalIF":2.6,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of community pharmacists' intention to provide pharmacist-driven vaccination services in selected Arabic-speaking countries: a theory of planned behaviour-based structural equation modelling study.","authors":"Ammar A Jairoun, Abeer M Al-Ghananeem, Moyad Shahwan, Heba Jeroudy, Sabaa S Al-Hemyari, Faris El-Dahiyat","doi":"10.1080/20523211.2026.2732501","DOIUrl":"10.1080/20523211.2026.2732501","url":null,"abstract":"<p><strong>Background: </strong>Community pharmacists are increasingly recognised as accessible healthcare providers who can contribute to immunisation programmes and improve vaccine coverage. However, pharmacist-driven vaccination services remain underutilised in many Arabic-speaking countries, and factors influencing pharmacists' intention to provide these services are not fully understood.</p><p><strong>Objective: </strong>To translate, culturally adapt, validate, and evaluate the Pharmacist-Driven Vaccination Service Intention Model (PDV-SIM) among community pharmacists in the United Arab Emirates, Saudi Arabia, and Qatar and identify factors influencing their intention to provide pharmacist-driven vaccination services.</p><p><strong>Methods: </strong>A cross-sectional online survey was conducted among community pharmacists practicing in Arabic-speaking countries between February 2024 and November 2024. The PDV-SIM was translated and culturally adapted using a forward-backward translation process. Confirmatory factor analysis and structural equation modelling were performed using EQS 6.4. Reliability, convergent validity, and discriminant validity were assessed using Cronbach's alpha, composite reliability, average variance extracted, and the Fornell-Larcker criterion.</p><p><strong>Results: </strong>A total of 305 pharmacists participated. The measurement model demonstrated acceptable fit under robust estimation (CFI = 0.936, IFI = 0.937, NNFI = 0.918, RMSEA = 0.066). Reliability and convergent validity were satisfactory across all constructs. The structural model also showed acceptable fit (CFI = 0.934, IFI = 0.935, TLI = 0.918, RMSEA = 0.065). Personal development attitude was the strongest predictor of intention to provide pharmacist-driven vaccination services (β = 0.724, <i>p</i> < 0.001), followed by subjective norm (β = 0.180, <i>p</i> < 0.01) and perceived behavioural control (β = 0.152, <i>p</i> < 0.05). The model explained 67.2% of the variance in intention.</p><p><strong>Conclusion: </strong>Professional development attitude, subjective norm, and perceived behavioural control significantly influenced pharmacists' intention to provide vaccination services. Strengthening training, professional support, and regulatory frameworks may facilitate implementation of pharmacist-driven vaccination services across Arabic-speaking countries.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2732501"},"PeriodicalIF":2.6,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal RSV vaccination: clinical efficacy, safety, and global policy considerations: a systematic review.","authors":"Khawla Abu Hammour, Qusai Manaseer, Murad Dweik, Walid Abu Hammour, Mohammed Zawiah, Faris El-Dahiyat, Rana K Abu-Farha","doi":"10.1080/20523211.2026.2728239","DOIUrl":"10.1080/20523211.2026.2728239","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Respiratory syncytial virus (RSV) is among the leading causes of lower respiratory tract illness in newborns worldwide. This study reviews evidence on the efficacy and safety of maternal RSV vaccination.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;PROSPERO registered this PRISMA-compliant systematic review (CRD42024566335). Keywords associated with RSV, respiratory infections, newborns, and immunisation were used in a search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane CENTRAL (inception to mid-2026). Because of the heterogeneity of the studies, a descriptive synthesis of the safety and efficacy data was performed instead of a formal meta-analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Sixteen publications - four real-world studies and twelve generated from nine separate parent trials/datasets (including three subgroup or subset analyses and post-hoc studies from two RCTs) - met the inclusion criteria. Depending on the dose, formulation, and length of follow-up, maternal immunisation was linked to a lower incidence of severe RSV-related lower respiratory tract infections in newborns, with efficacy/effectiveness varying from roughly 39% to 100%. Trial-based efficacy results were generally in line with real-world effectiveness data from national and multicenter initiatives in the US, UK, and Argentina. Preterm birth outcomes differed depending on the formulation: a bivalent RSVpreF vaccine (Pfizer MATISSE trial; [Li, Y., Wang, X., Blau, D. M., Caballero, M. T., Feikin, D. R., Gill, C. J., Madhi, S. A., Omer, S. B., Simões, E. A. F., & Campbell, H. (2022). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. &lt;i&gt;The Lancet&lt;/i&gt;, &lt;i&gt;399&lt;/i&gt;(10340), 2047-2064; Otsuki, T., Akada, S., Anami, A., Kosaka, K., Munjal, I., Baber, J., Shoji, Y., Aizawa, M., Swanson, K. A., & Gurtman, A. (2024). Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial. &lt;i&gt;Vaccine&lt;/i&gt;, &lt;i&gt;42&lt;/i&gt;(22), 126041]) did not exhibit this association in post-hoc analyses, while an unadjuvanted RSVpreF vaccine (GSK; [Dieussaert, I., Hyung Kim, J., Luik, S., Seidl, C., Pu, W., Stegmann, J.-U., Swamy, G. K., Webster, P., & Dormitzer, P. R. (2024). RSV prefusion F protein-based maternal vaccine - preterm birth and other outcomes. &lt;i&gt;New England Journal of Medicine&lt;/i&gt;, &lt;i&gt;390&lt;/i&gt;(11), 1009-1021]) showed a significant increase in preterm birth (RR 1.37, 95% CI 1.08-1.74). Although post-vaccination responses were frequent, they were usually mild to moderate.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;There was no discernible rise in major adverse outcomes for mothers or newborns. Real-world data from a variety of situations now supports the conclusion that maternal RSV vaccination consistently decreased newborn RSV hos","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2728239"},"PeriodicalIF":2.6,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13587576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of pharmacy professionals' workplace satisfaction in a conflict-affected health system: evidence from Yemen.","authors":"Najmaddin A H Hatem","doi":"10.1080/20523211.2026.2726600","DOIUrl":"10.1080/20523211.2026.2726600","url":null,"abstract":"<p><p>Job satisfaction among pharmacy professionals is a key determinant of workforce retention and quality of pharmaceutical care. Yemen represents an extreme case in which prolonged conflict, economic collapse, and fragmented health governance may fundamentally reshape the professional-organisational relationship. A descriptive cross-sectional survey was conducted among pharmacy professionals in Yemen using a self-administered electronic questionnaire. Job satisfaction was assessed across five domains: <i>Management and organisational support, Work environment, Inter-professional relationships, Compensation and rewards,</i> and <i>Professional satisfaction</i>. Non-parametric statistical tests and Spearman correlation analyses were applied. A total of 106 pharmacy professionals participated in the study. Overall job satisfaction was moderate (median 3.33, IQR 2.84-3.84). Professional satisfaction was the highest-rated domain with median and IQR 3.83(3.04-4.17), with 68.9% of pharmacists reporting pride in their work and 63.2% indicating they would choose the profession again. Inter-professional relationships ranked second with median and IQR of 3.57(3.14-4.14), with 79.3% reporting strong collegial respect. In contrast, Compensation and rewards constituted a critical source of dissatisfaction, with only 16.0% of respondents perceiving their salary as fair. Years of professional experience was significantly associated with overall satisfaction (<i>p</i> = 0.01), with more experienced pharmacists reporting lower satisfaction. All satisfaction domains were positively correlated, with the strongest association observed between Work environment and Management and organisational support (ρ = 0.720). This study suggests that pharmacy professionals in Yemen maintain strong professional commitment and positive inter-professional relationships despite substantial dissatisfaction with compensation and other extrinsic employment conditions. The observed inverse association between professional experience and job satisfaction may indicate changing professional expectations among more experienced pharmacists, although the underlying mechanisms require further investigation. These findings contribute to the limited evidence on pharmacy workforce satisfaction in conflict-affected settings and may inform context-sensitive workforce policies in fragile and resource-constrained health systems.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2726600"},"PeriodicalIF":2.6,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13577269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension prevalence in the Asia-Pacific region: a systematic analysis of population-based studies.","authors":"Phayom Sookaneknun Olson, Todd A Lee, Jyotirmoy Sarker, Ratree Sawangjit, Bee Kim Tan, Wanarat Anusornsangiam, Christianus Heru Setiawan, Charles Mandy Ayran, Chanuttha Ploylearmsang, Nurolaini Kifli, Suntaree Watcharadamrongkun, Santiparp Sookaneknun, Hung Nguyen Van, Phoutsathaphone Sibounheuang, Pemmarin Potisarach, Lim Ai Fern, Thi Lien Ngo, Nathorn Chaiyakunapruk, Chalongchai Thundee, Areerut Leelathanalerk","doi":"10.1080/20523211.2026.2727205","DOIUrl":"10.1080/20523211.2026.2727205","url":null,"abstract":"<p><p><b>Background:</b> A large proportion of the world population lives in the Asia-Pacific region where uncontrolled hypertension impacts global trends. This study aimed to summarise age-adjusted prevalence estimates of hypertension in the region to project the future burden of the disease to 2030. <b>Methods:</b> A comprehensive literature search was conducted using PubMed®, Web of Science®, SCOPUS®, and Embase®, alongside manual reference reviews, to identify studies from 2001 to 2023 in the Asia-Pacific region. Inclusion criteria required standardised blood pressure measurement, population-based data, and definitions of hypertension as systolic and diastolic ≥140/90 mmHg, or antihypertensive use. The hypertension prevalence was determined based on the identified studies. Within countries, the linear regression of age-standardised prevalence estimates predicted trends in hypertension prevalence to 2030. <b>Results:</b> 285 population-based studies were included. Age-specific and crude hypertension prevalence estimates from 19 countries were used to estimate predicted values. The estimated age-standardised prevalence of hypertension in 2030 ranged from 11.0% to 46.2% and was projected to increase in most countries. The exceptions were Iran, Nepal, and Mongolia, which were estimated to achieve 30% reduction in hypertension relative to 2010. Six countries were estimated to have reductions in prevalence by 2030, but without achieving the WHO goal of 30% reduction relative to 2010. <b>Conclusion:</b> The hypertension prevalence has been increasing in most countries. Only three countries are projected to achieve their target goal by 2030. Initiatives to strengthen primary prevention and treatment, along with consistent measurement of population blood pressure in this region, should remain important agenda items for policy makers.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2727205"},"PeriodicalIF":2.6,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13577282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The future of pharmaceuticals: strategic foresight in an era of uncertainty.","authors":"Kateryna Ostrovska","doi":"10.1080/20523211.2026.2724624","DOIUrl":"10.1080/20523211.2026.2724624","url":null,"abstract":"","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2724624"},"PeriodicalIF":2.6,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13577300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}